Bladder Cancer Trial, Recruiting NCT03193541 Sponsor: Cedars-Sinai Medical Center Condition: Bladder Cancer
Back to Bladder Cancer

Bladder Cancer Trial, Recruiting

NCT03193541
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are 18 years of age or older
  • People who have had microscopic blood in their urine (too small to see with the naked eye) recorded or reported within the last 3 months before joining the study
  • People who are willing and able to sign a written consent form

Who may not be able to join:

  • People who have a history of bladder cancer
  • People who have a history of any other cancer (not including certain common types of skin cancer — basal cell or squamous cell skin cancer)
  • People who currently have a known urinary tract infection or are unable to pass urine normally
  • People who have active kidney stones or bladder stones, or have reduced kidney function (confirm with trial site)
  • People who have ureteral stents, nephrostomy tubes, or bowel tissue used in the urinary tract (confirm with trial site)
  • People who have had any recent procedures or instruments used in the urinary or genital area within the 10 days before signing the consent form
  • People who are unable or unwilling to complete the required bladder and kidney investigations, which include a camera examination of the bladder and imaging of the upper urinary tract

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Charles Rosser, MD, Nonagen Bioscience Corporation

Phone: 310-423-5609

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Cedars-Sinai Medical Center
Registry
ClinicalTrials.gov
Start date
30 December 2016
Est. completion
1 February 2029

Where this trial is recruiting

🇯🇵 Japan 🇺🇸 United States

Primary endpoints

Sensitivity and specificity of multiplex ELISA assay will be confirmed by cystoscopy.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov